Survodutide: The Next GLP-1/Glucagon Dual Agonist for Weight Loss (2026 Guide)
Survodutide is a dual GLP-1/glucagon receptor agonist in phase 3 trials for obesity and MASH. Learn how it works, trial results, expected approval, and comparison to Wegovy and Zepbound.
Start your GLP-1 weight-loss plan from $147/month
Take our 60-second quiz to get matched with a US-licensed provider. Approved online — medication shipped to your door in 3-5 days.
See if I qualify — Free 60-sec quizAvailable online. Shipped directly to your door anywhere in the US.
Quick answer: What is survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist currently in phase 3 clinical trials for both obesity and MASH (metabolic dysfunction-associated steatohepatitis). Developed by Boehringer Ingelheim and Zealand Pharma, it targets both GLP-1 and glucagon receptors — a mechanism that may produce greater weight loss and liver benefits than GLP-1-only medications. Phase 2 results showed up to 19% weight loss, comparable to tirzepatide. FDA approval could come as early as 2027 or 2028.
How survodutide works
Survodutide is a dual receptor agonist that targets two key metabolic pathways:
- GLP-1 receptor — Suppresses appetite, slows gastric emptying, improves insulin sensitivity, and reduces blood sugar. This is the same mechanism as semaglutide (Wegovy) and tirzepatide (Zepbound).
- Glucagon receptor — Promotes fat burning (lipolysis), increases energy expenditure, and may have direct liver-protective effects. This is unique to survodutide and retatrutide among GLP-1 pipeline drugs.
The dual GLP-1/glucagon mechanism is particularly exciting for MASH patients, because the glucagon component may provide direct liver benefits that GLP-1-only medications do not offer.
Clinical trial results
Phase 2 obesity results
- Up to 19% weight loss at higher doses
- Weight loss was dose-dependent — higher doses produced more weight loss
- Results were comparable to tirzepatide (Zepbound) in similar trial populations
- Side effects were primarily gastrointestinal (nausea, diarrhea) and generally manageable
Phase 3 trials (ongoing)
- Obesity indication — Large-scale trials to confirm weight loss efficacy and safety
- MASH indication — Evaluating MASH resolution and fibrosis improvement
- Results expected in 2026 to 2027, with potential FDA filing thereafter
Survodutide vs other GLP-1 medications
| Drug | Mechanism | Max weight loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 only | ~15% | FDA-approved |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~22.5% | FDA-approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Phase 3 |
| Survodutide | GLP-1 + Glucagon | ~19% | Phase 3 |
| CagriSema | GLP-1 + Amylin | ~22.7% | Phase 3 |
See our guides on retatrutide, retatrutide vs tirzepatide, and CagriSema.
Survodutide for MASH
One of the most exciting aspects of survodutide is its potential for MASH treatment. The glucagon receptor component may provide direct liver-protective effects:
- Glucagon receptor activation may reduce hepatic fat accumulation
- Dual mechanism addresses both obesity (the root cause) and liver inflammation directly
- Phase 2 data showed significant MASH resolution rates
- May be especially beneficial for patients with MASH and advanced fibrosis
See our semaglutide for MASH guideand GLP-1 and fatty liver guide.
Expected approval timeline
- Phase 3 trials — Ongoing, results expected 2026 to 2027
- FDA filing — 2027 (estimated, depending on trial results)
- FDA approval — 2027 to 2028 (estimated)
- Market launch — 2028 (estimated)
Note: Timelines are estimates and may change based on trial results and regulatory review.
Side effects
Survodutide's side effect profile is similar to other GLP-1 medications:
- Nausea (most common)
- Diarrhea
- Constipation
- Fatigue
- Vomiting (less common)
The glucagon component may cause additional gastrointestinal effects. Phase 3 trials are collecting comprehensive safety data. See our GLP-1 side effects guide.
Survodutide vs retatrutide
Both survodutide and retatrutide target the glucagon receptor, but retatrutide is a triple agonist (GLP-1 + GIP + glucagon) while survodutide is a dual agonist (GLP-1 + glucagon). Retatrutide may achieve slightly more weight loss due to the additional GIP component (~24% vs ~19%), but survodutide's dual mechanism may be sufficient for many patients, especially those focused on liver health. See our retatrutide guide.
FAQ
What is survodutide?
A dual GLP-1/glucagon receptor agonist in phase 3 trials for obesity and MASH, developed by Boehringer Ingelheim and Zealand Pharma.
How does survodutide work?
It targets both GLP-1 receptors (appetite suppression, blood sugar control) and glucagon receptors (fat burning, liver protection). The dual mechanism may produce greater weight loss and liver benefits.
How much weight can you lose on survodutide?
Phase 2 results showed up to 19% weight loss at higher doses, comparable to tirzepatide. Phase 3 trials are confirming these results.
When will survodutide be approved?
FDA approval could come as early as 2027 or 2028, depending on phase 3 trial results and regulatory review.
Is survodutide better than Wegovy or Zepbound?
Phase 2 data suggests weight loss comparable to Zepbound and greater than Wegovy. The glucagon component may provide additional liver benefits. Definitive comparison awaits phase 3 results.
Can survodutide treat MASH?
Yes, survodutide is being studied for MASH in phase 3 trials. The glucagon component may provide direct liver-protective effects beyond GLP-1-only medications.
What are the side effects of survodutide?
Similar to other GLP-1s: nausea, diarrhea, constipation, fatigue. The glucagon component may cause additional GI effects.
How is survodutide different from retatrutide?
Survodutide is a dual GLP-1/glucagon agonist; retatrutide is a triple GLP-1/GIP/glucagon agonist. Retatrutide may achieve slightly more weight loss due to the additional GIP component.
Related articles
Ready to start? Get GLP-1 prescribed online this week
Join 50,000+ patients who lost 15-22% of body weight with the right GLP-1 medication. Free consultation — no insurance needed.
Check if I qualify — Free 60-sec quizAvailable online. Shipped directly to your door anywhere in the US.
Real patients. Real results.
Join 50,000+ patients who transformed their lives with GLP-1 medications
"I tried everything — keto, intermittent fasting, gym memberships. Nothing worked long-term. GLP-1 changed everything. I lost 47 pounds in 8 months and finally feel like myself again. The online process was so easy — I had my prescription in 2 days."
Jessica M., 38
Texas
-47 lbs
in 8 months
Compounded semaglutide
"At 52, my doctor said I was heading toward diabetes. I started tirzepatide through a telehealth program and lost 62 pounds. My A1C is back to normal, my blood pressure dropped, and I'm off two medications. Wish I'd done this years ago."
David R., 52
Florida
-62 lbs
in 11 months
Tirzepatide (Zepbound)
"I was skeptical about doing this online, but the whole process was professional and easy. My provider answered all my questions, and the medication arrived in 4 days. I've lost 38 pounds and finally have energy to play with my kids again."
Aisha K., 34
California
-38 lbs
in 6 months
Compounded semaglutide
Results vary. These testimonials reflect individual experiences and are not typical. Weight loss depends on diet, activity, and adherence to medication.
How it works — 3 simple steps
Take the 60-second quiz
Answer a few questions about your health, weight goals, and medical history. It's free and confidential.
1 min
Meet your US-licensed provider
A board-certified clinician reviews your profile and prescribes the right GLP-1 medication for you — entirely online.
24-48 hrs
Get medication shipped to your door
Your prescription is filled by a US pharmacy and delivered in discreet packaging in 3-5 business days.
3-5 days
Get GLP-1 savings alerts & weekly tips
Join 50,000+ readers. Price drops, new coupons, and expert weight-loss advice — delivered weekly. Unsubscribe anytime.
Free. No spam. Unsubscribe anytime.